Business UpdateAug 5, 2026, 12:08 PM
20/20 Biolabs Reports Record Q2 Cancer Testing Revenue, New Pilots
AI Summary
20/20 Biolabs, Inc. announced preliminary Q2 2026 results, marking its best quarterly cancer testing revenue to date, with strong year-over-year growth anticipated for Q3 and Q4. The company secured 29 new accounts and was selected for the Vermont Firefighter Cancer Screening Program. Additionally, 20/20 Biolabs launched a pilot program with Giant Food for its OneTest for Longevity and highlighted the recent passage of the Multi-Cancer Early Detection Screening Coverage Act, which could enable Medicare reimbursement by 2028.
Key Highlights
- Reported Q2 2026 as the best quarterly cancer testing revenue to date (preliminary).
- Expects strong year-over-year revenue growth for Q3 and Q4 2026.
- Secured 29 orders from new accounts, including occupational health and fire departments.
- Selected for Vermont Firefighter Cancer Screening Program, screening up to 4,500 firefighters.
- Launched a 3-month pilot with Giant Food for OneTest for Longevity, starting August 2026.
- CEO completed a two-week East Asia trip for commercial expansion and M&A opportunities.
- Congress passed the Multi-Cancer Early Detection Screening Coverage Act for Medicare by 2028.
Price Impact
More from AIDX